Pertuzumab–Docetaxel–Trastuzumab regimen in HER2-positive metastatic breast cancer: Real-world data from India

Purpose: Dual human epidermal growth factor receptor 2 (HER2) blockade with pertuzumab and trastuzumab plus chemotherapy is the standard first-line treatment for HER2-positive metastatic breast cancer (BC), as per the CLEOPATRA trial. However, real-world data from low- and middle-income countries (L...

Полное описание

Библиографические подробности

Главные авторы:	Ajay Gogia, Atul Batra, Ashutosh Mishra, Kamal Kataria, Surendra K Saini, Sandeep Mathur, Chandra P Prasad, Hari Krishna Raju Sagiraju
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Elsevier 2026-01-01
Серии:	Cancer Treatment and Research Communications
Предметы:	HER2-positive Metastatic breast cancer Adjuvant therapy PTH regimen Progression-free survival overall survival
Online-ссылка:	http://www.sciencedirect.com/science/article/pii/S2468294226001073
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!